S L Meeks
Overview
Explore the profile of S L Meeks including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
556
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Design and characterization of a prototype tertiary device for proton beam stereotactic radiosurgery
Willoughby T, Boczkowski A, Meeks S, Bova F, Zeidan O, Erhart K, et al.
Biomed Phys Eng Express
. 2021 Jun;
7(4).
PMID: 34087816
Though potentially beneficial, proton beam stereotactic radiosurgery has not been adopted widely secondary to the technical challenge of safely delivering multiple focused beams of proton radiation. In this study, we...
2.
Reipert B, Gangadharan B, Hofbauer C, Berg V, Schweiger H, Bowen J, et al.
Blood Adv
. 2020 Nov;
4(22):5785-5796.
PMID: 33232473
Preventing factor VIII (FVIII) inhibitors following replacement therapies with FVIII products in patients with hemophilia A remains an unmet medical need. Better understanding of the early events of evolving FVIII...
3.
Boczkowski A, Kelly P, Meeks S, Erhart K, Bova F, Willoughby T
J Appl Clin Med Phys
. 2020 Nov;
21(12):96-108.
PMID: 33151014
For many patients, stereotactic radiosurgery (SRS) offers a minimally invasive, curative option when surgical techniques are not possible. To date, the literature supporting the efficacy and safety of SRS treatment...
4.
Batsuli G, Ito J, Mercer R, Baldwin W, Cox C, Parker E, et al.
J Thromb Haemost
. 2018 Jul;
16(9):1779-1788.
PMID: 29981270
Summary: Background The development of neutralizing anti-factor VIII (FVIII) antibodies remains a challenging complication of modern hemophilia A care. In vitro assays are the primary method used for quantifying inhibitor...
5.
Batsuli G, Meeks S, Herzog R, Lacroix-Desmazes S
Haemophilia
. 2016 Jul;
22 Suppl 5:31-5.
PMID: 27405673
Introduction: Haemophilia A is an X-linked bleeding disorder characterized by a deficiency of coagulation protein factor VIII (FVIII). A challenging complication of therapeutic FVIII infusions is the formation of neutralizing...
6.
Chao B, Baldwin W, Healey J, Parker E, Shafer-Weaver K, Cox C, et al.
J Thromb Haemost
. 2015 Nov;
14(2):346-55.
PMID: 26588198
Unlabelled: ESSENTIALS: Anti-factor VIII (FVIII) inhibitory antibody formation is a severe complication in hemophilia A therapy. We genetically engineered and characterized a mouse model with complete deletion of the F8...
7.
Valentino L, Kempton C, Kruse-Jarres R, Mathew P, Meeks S, Reiss U
Haemophilia
. 2015 Jun;
21(5):559-67.
PMID: 26032231
Introduction: The development of anti-factor VIII (FVIII) antibodies (inhibitors) is the most serious treatment-related complication in patients with hemophilia A, rendering standard replacement therapy ineffective, heightening the risk for uncontrollable...
8.
Zakas P, Vanijcharoenkarn K, Markovitz R, Meeks S, Doering C
J Thromb Haemost
. 2014 Oct;
13(1):72-81.
PMID: 25315236
Background: The formation of neutralizing antibodies (inhibitors) directed against human coagulation factor VIII (hFVIII) is a life-threatening pathogenic response that occurs in 20-30% of severe congenital hemophilia A patients and...
9.
Tran D, Harvey R, Meeks S, Chapman R, Kempton C
Haemophilia
. 2014 Apr;
20(4):e344-6.
PMID: 24750497
No abstract available.
10.
Sevy A, Healey J, Deng W, Spiegel P, Meeks S, Li R
J Thromb Haemost
. 2013 Oct;
11(12):2128-36.
PMID: 24152306
Background: The development of anti-factor VIII antibodies (inhibitors) is a significant complication in the management of patients with hemophilia A, leading to significant increases in morbidity and treatment cost. Using...